# Bolt Biotherapeutics, Inc.

**BOLT**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001641281

**E**

**weakest fifth of 370 graded peers in healthcare**

rank 355 of 370; percentile 95.9; sampling error 2.5 points; lower is stronger


A B C D E

**E, the bear**




| Scoreboard | |
|---|---|
| **Profitability** | E<br>percentile 90.1 |
| **Solvency** | D<br>percentile 75.0 |
| **Growth and financing** | C<br>percentile 53.2 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $56.7M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, distress<br>not computable: fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 12, 2026<br>222 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $4.08<br>2026-10-19; market equity $7.9M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 12, 2026*

Our mission is to harness the power of the immune system to improve lives and eradicate cancer. This often means that our product candidates take new and unproven approaches to treating cancer. We believe that taking smart risks is critical to making breakthroughs. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our various approaches use pattern recognition receptors expressed by the innate immune system to help the body eliminate tumor cells as part of a productive anti-cancer response.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 90.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | 8.3% | (6.6%) | | 90.1 | 812 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 75.0** | | | | | | |
| Twelve-month failure probability | 4.57% | 0.06% | | 95.5 | 247 | 2026-06-30 |
| Altman Z double-prime | (27.30) | (0.30) | | 78.8 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 3.59x | 2.96x | | 50.8 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 53.2** | | | | | | |
| Revenue growth, three-year compound | 10.3% | 10.1% | | 49.9 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | (37.1%) | 2.1% | | 95.3 | 705 | 2025-12-31 |
| Net share issuance, one year | 0.2% | 2.5% | | 14.5 | 634 | 2026-03-06 |


## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 4.9 months |
| Distress | CHS probability 4.567086%; universe top-decile threshold 0.908785% |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 350 | Kyntra BIO, Inc. (KYNB) | 94.6 | E | |
| 351 | Silo Pharma, Inc. (SILO) | 94.9 | E | dilution, degenerate inputs, distress |
| 352 | VivoSim Labs, Inc. (VIVS) | 95.1 | E | dilution, short runway, late filer |
| 353 | Biomerica Inc. (BMRA) | 95.4 | E | |
| 354 | ALX Oncology Holdings Inc. (ALXO) | 95.7 | E | dilution, short runway, degenerate inputs, fortress balance sheet |
| 355 | Bolt Biotherapeutics, Inc. (BOLT) | 95.9 | E | short runway, distress |
| 356 | Pfizer Inc. (PFE) | 96.2 | E | |
| 357 | Dare Bioscience, Inc. (DARE) | 96.5 | E | dilution |
| 358 | Longeveron Inc. (LGVN) | 96.7 | E | short runway |
| 359 | Clene Inc. (CLNN) | 97.0 | E | dilution, distress |
| 360 | Agenus Inc. (AGEN) | 97.3 | E | dilution, short runway |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (25.2%) | 8.0% | 28 |
| Distance from 52-week high | (43.0%) | (31.9%) | 34 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (513.0%) | (1.0%) | 2 |
| Book value to price | 1.62 | 0.28 | 93 |
| Sales to price | 0.99 | 0.31 | 81 |
| Composite equity issuance, five years | not computable | 20.3% | |
| Relative strength against the sector, log excess return | (0.50) | (0.13) | 28 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $12.9M |
| Operating cash flow, four quarters | -$31.5M |
| Months of runway | 4.9 |
| Days since last periodic filing | 70 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $54,870 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$33.4M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$39.9M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 3 | assets | us-gaap:Assets | $56.7M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 4 | assets | us-gaap:Assets | $99.6M | 2024-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 5 | current assets | us-gaap:AssetsCurrent | $30.3M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $8.4M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$460.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$36.1M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 9 | book equity | us-gaap:StockholdersEquity | $26.5M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 10 | liabilities | us-gaap:Liabilities | $30.2M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 11 | revenue | us-gaap:Revenues | $7.7M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 12 | revenue | us-gaap:Revenues | $7.7M | 2024-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 13 | revenue | us-gaap:Revenues | $7.9M | 2023-12-31 | 2025-03-24 | 10-K | 25-043873 |
| 14 | revenue | us-gaap:Revenues | $5.7M | 2022-12-31 | 2024-03-21 | 10-K | 24-034692 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $72,000 | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$61.3M | 2024-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $41,000 | 2024-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$69.5M | 2023-12-31 | 2025-03-24 | 10-K | 25-043873 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $206,000 | 2023-12-31 | 2025-03-24 | 10-K | 25-043873 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$76.5M | 2022-12-31 | 2024-03-21 | 10-K | 24-034692 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.0M | 2022-12-31 | 2024-03-21 | 10-K | 24-034692 |
| 22 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $1.3M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 23 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$33.4M | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 24 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 25 | current assets | us-gaap:AssetsCurrent | $50.8M | 2024-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $15.9M | 2024-12-31 | 2026-03-12 | 10-K | 26-104121 |
| 27 | assets | us-gaap:Assets | $159.8M | 2023-12-31 | 2025-03-24 | 10-K | 25-043873 |
| 28 | assets | us-gaap:Assets | $227.8M | 2022-12-31 | 2024-03-21 | 10-K | 24-034692 |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,921,567 | 2026-03-06 | 2026-03-12 | 10-K | 26-104121 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 38,339,697 | 2025-03-19 | 2025-03-24 | 10-K | 25-043873 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.